ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions
View by Date

Sunday, November 10, 2019

9:00AM-11:00AM
Abstract Number: 522
Treatment with Upadacitinib Results in the Normalization of Key Pathobiologic Pathways in Patients with Rheumatoid Arthritis
RA – Treatments Poster I: Novel Treatments
9:00AM-11:00AM
Abstract Number: 94
Tumor Necrosis Factor Receptor 2 Signaling Potentiates Proliferation and Suppressive Activities of Follicular Regulatory T Cells
T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster
9:00AM-11:00AM
Abstract Number: 788
Type I Interferon Score and Interferon Induced Mediators CXCL10 and Neopterin Are Correlated with Disease Activity in Juvenile Dermatomyositis
Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever
9:00AM-11:00AM
Abstract Number: 88
Type I Interferon Signature Activation in Antiphospholipid Syndrome: Gene Expression Heterogeneity Among Disease Subsets
T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster
9:00AM-11:00AM
Abstract Number: 297
Ultrasound and Magnetic Resonance Imaging Evaluation of the Fingers’ Joints of Psoriatic Arthritis Patients – Interim Analysis
Imaging Of Rheumatic Diseases Poster I
9:00AM-11:00AM
Abstract Number: 287
Ultrasound Evaluation of the Achilles Enthesis in Inflammatory and Non-inflammatory Processes: A Systematic Review
Imaging Of Rheumatic Diseases Poster I
9:00AM-11:00AM
Abstract Number: 711
Ultrasound Evaluation of the Hands in Patients with Systemic Sclerosis: Osteophytosis Is a Major Contributor to Tender Joints
Systemic Sclerosis & Related Disorders – Clinical Poster I
9:00AM-11:00AM
Abstract Number: 282
Ultrasound Is More Sensitive Compared to Conventional Radiography to Detect Joint Erosions in ACPA-positive Patients with Musculoskeletal Pain
Imaging Of Rheumatic Diseases Poster I
9:00AM-11:00AM
Abstract Number: 721
Ultrasound Measurement of the Nail Bed Matrix Thickness as a Useful Marker for Scleroderma-Related Interstitial Lung Disease
Systemic Sclerosis & Related Disorders – Clinical Poster I
9:00AM-11:00AM
Abstract Number: 280
Ultrasound versus Conventional Treat-To-Target Strategies in Early Rheumatoid Arthritis: Magnetic Resonance Imaging Outcome Data from a 2-year Randomized Controlled Strategy Trial
Imaging Of Rheumatic Diseases Poster I
9:00AM-11:00AM
Abstract Number: 78
Ultraviolet Light Induces Increased T Cell Activation in Lupus-Prone Mice via Type I Interferon-Dependent Inhibition of T Regulatory Cells
SLE – Animal Models Poster
9:00AM-11:00AM
Abstract Number: 796
Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests: Results from the Juvenile Scleroderma Inception Cohort
Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever
9:00AM-11:00AM
Abstract Number: 568
Understanding mNY Radiograph Score Discordance in Axial Spondyloarthritis Clinical Trials Using Imaging Criteria for Subject Eligibility
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features
9:00AM-11:00AM
Abstract Number: 367
Understanding the Mystery of Sarcoidosis: An Academic Rheumatology Center Experience
Miscellaneous Rheumatic & Inflammatory Disease Poster I: Fibroinflammatory & Granulomatous Disorders & Therapies
9:00AM-11:00AM
Abstract Number: 435
Understanding Which Patient-Reported Outcomes Are Important to Rheumatology Patients: Findings from ArthritisPower
Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes
  • «Previous Page
  • 1
  • …
  • 49
  • 50
  • 51
  • 52
  • 53
  • …
  • 65
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology